YOKNEAM, Israel, May 13 /PRNewswire/ -- Lumenis Inc., a global developer, manufacturer and seller of laser, light-based and radiofrequency devices for surgical, aesthetic, and ophthalmic applications, announced today the launch of a Holmium Laser Enucleation of the Prostate (HoLEP) preceptor program that will provide training opportunities for urologists who are interested in learning and performing HoLEP. The abundance of clinical evidence suggests that HoLEP provides superior outcomes in treating Benign Prostatic Hyperplasia (BPH) of all gland sizes(1). For large prostates, HoLEP is a surgical laser procedure that has been shown to be safe and effective(1,2,3). At this year's AUA meeting, there will be a series of speeches, skills labs and roundtable discussions that will feature HoLEP. For details visit http://www.GetPowerSuite.com.
Patients are commonly put on medication as an initial treatment for BPH. The effect of medical therapy is limited and urologists are increasingly seeing patients with larger prostates by the time they are referred for surgery. TURP, transurethral resection of the prostate, has been the standard surgical procedure for the treatment of BPH, however, the body of clinical evidence now shows that HoLEP provides a superior treatment outcome and durability(2).
"I have been a firm believer in HoLEP as it is the most clinically proven laser treatment for BPH," said Dr. Mostafa Elhilali, Chair, Department of Surgery, McGill University. "It is good to see that the company is providing the proper resources to ensure that this procedure is properly adopted by the broader urology community worldwide."
Dr. James Lingeman, Clinical Professor of Urology, Indiana University
School of Medicine, stated, "There are many treatment modalities for BPH,
however, none have the history of proven clinical outcomes for prostates of
any size that HoLEP has. I have trained many phy
|SOURCE Lumenis Ltd.|
Copyright©2008 PR Newswire.
All rights reserved